Compare Bristol-Myers Squibb Co (BMY) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Meta Platforms Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.41 (market cap $116.30B), while Meta Platforms Inc trades at $658.7 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 14.4× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | META | |
|---|---|---|
Market Cap | $116.30B | $1.68T |
Sector | Health | Media |
52-Week High | $62.37 | $790.00 |
52-Week Low | $42.60 | $525.72 |
Enterprise Value | $152.24B | $1.68T |
Dividend Yield | 4.42% | 0.32% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
META stock trades at $665.31, up 1.31% over the past 24 hours, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected, driven by revenue growth to $201.0 billion in 2025. Positive sentiment is fueled by the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though legal challenges over youth addiction persist.
Outlook remains favorable given analyst consensus price target of $815.44 and 79% buy ratings, supported by high profitability margins and AI monetization potential. Key risks include regulatory lawsuits and elevated capital expenditures impacting cash flow. The stock offers growth exposure but requires monitoring of legal outcomes and competitive dynamics in social media and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
